Jonathan Schoenfeld, MD, MPH, discusses the immunologic effects of chemotherapy plus radiation, as well as radiation alone.
Jonathan Schoenfeld, MD, MPH, attending radiation oncologist, assistant professor, Harvard Medical School, Dana Farber Cancer Institute/Brigham and Women's Hospital, discusses the immunologic effects of chemotherapy plus radiation, as well as radiation alone.
Schoenfeld says he and his team looked at chemokines, part of the cytokines family, and their mediation abilities outside the treatment field, as well as circulating T cells. He adds that some T cells investigated included CD8-positive T cells, CD4-positive T cells, as well as markers of active T cells and T regulatory cells.
Schoenfeld says chemotherapy and radiation have long been used for their immune suppressive effects, though chemotherapy and radiation given in a certain way can cause immunologic cell death. This ability could synergize with immunotherapy and immune checkpoint blockade treatments currently being developed.
FDA Grants Fast Track Designation to MVR-T3011 in HNSCC
March 20th 2024The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More